Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Oct 5;11(10):e0005957.
doi: 10.1371/journal.pntd.0005957. eCollection 2017 Oct.

Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial

Mohammad Mahdi Parvizi  1   2   3 , Farhad Handjani  2   4 , Mahmoodreza Moein  5   6 , Gholamreza Hatam  7 , Majid Nimrouzi  1   3 , Jafar Hassanzadeh  8 , Nasrin Hamidizadeh  2 , Hamid Reza Khorrami  9 , Mohammad Mehdi Zarshenas  5   10
Affiliations
Randomized Controlled Trial

Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial

Mohammad Mahdi Parvizi et al. PLoS Negl Trop Dis. .

Abstract

Background: Cutaneous leishmaniasis is one of the highly prevalent endemic diseases in the Middle East and North Africa. Many treatment modalities have been recommended for this condition but success rates remain limited. Herbal remedies have also been used for treatment but evidence-based clinical trials with these products are sparse. In-vitro and in-vivo studies have shown the anti-leishmanial and curative effects of extract of fruits and leaves of Juniperus excelsa (J. excelsa). The aim of this study was to determine the efficacy of topical J. excelsa M. Bieb extract as an adjuvant to cryotherapy for the treatment of human CL.

Materials and methods: This study was designed as a two-arm triple-blind randomized placebo-controlled clinical trial using a parallel design. Seventy-two patients with clinical diagnosis of CL confirmed by leishmania smears were allocated to receive either a topical formulation of leaf of J. excelsa extract (group A) or placebo (group B) for 3 months. Both groups received cryotherapy as baseline standard treatment. Patients were evaluated before and weekly after the intervention was initiated until complete cure.

Results: Overall, 82% of patients in group A, experienced complete cure and 9% of them had partial cure. On the other hand, 34% in group B reported complete cure, while 14% of them had partial cure at the end of treatment protocol with a significant difference between the two groups (P< 0.001). The mean duration to healing of the lesions in patients who received J. excelsa extract was statistically significantly shorter than the placebo group (p = 0.04). No significant side effect was seen in the J. excelsa extract group except for mild to moderate local irritation after a few weeks in a few numbers of patients.

Conclusion: The results of this study showed that topical J. excelsa extract can be used as an adjuvant treatment modality in addition to cryotherapy for accelerating the time to cure in addition to increasing the complete cure rate in CL.

Trial registration: ClinicalTrials.gov IRCT2015082523753N1.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. CONSORT chart of the clinical trial of therapeutic effect of Juniperus excelsa M. Bieb extract cream on cutaneous leishmaniasis.
Fig 2
Fig 2. Electrophoresis of PCR products of DNA extracted from positive smears.
The 15 lanes are shown in this figure and consist of: ladder lanes (1 and 15); weakly positive (lane 2); positive control of L. infantum (lane 3); positive control of L. major (lane 14); Patients samples (lanes 4–13).
Fig 3
Fig 3. Changes in the size of CL lesions in both groups during three months.
The numbers on the left side of the chart indicate the changes of length of the ulcers (mm) and the numbers on right side of the chart indicate the area changes (mm2) in the duration of treatment (12 weeks).
Fig 4
Fig 4. CL patient who was cured in group A.
(A)Before treatment, (B)after one week, (C) after two weeks, (D)after three weeks, (E) after five weeks.
See this image and copyright information in PMC

References

    1. Sundar S, Longo D, Fauci A, Kasper D, Hauser S, Jameson J, et al. Leishmaniasis,. Harrison's Principles of Internal Medicine, 18th Edition 18th Edition ed. New York: McGraw-Hill Medical Publishing Division; 2011.
    1. Habif T. Clinical Dermatology. 5 ed. USA: Mosby; 2010. 1040 p.
    1. Azizi MH, Bahadori M, Dabiri S, Shamsi Meymandi S, Azizi F. A History of Leishmaniasis in Iran from 19th Century Onward. Archives of Iranian medicine. 2016;19(2):153–62. Epub 2016/02/04. doi: 0161902/AIM.0016 . - PubMed
    1. Bray R. Note on the history of cutaneous leishmaniasis in the Mediterranean and Middle East area. Parassitologia. 1986;29(2–3):175–9 . - PubMed
    1. Avicenna H. The Canon in Medicine. Beirut: Institute of Al-A'lami Li Al-Matbooat; 2005.

Publication types

MeSH terms